PharmaTutor (January- 2014)
ISSN: 2347 - 7881
Received On: 21/12/2013; Accepted On: 07/01/2014; Published On: 15/01/2014
About Authors: Abhishek Shah*, Gautam Singhvi
Department of Pharmacy, Industrial Research Lab,
Birla Institute of Technology and Science,
Pilani, Rajasthan, India.
ABSTRACT: Dendrimers are a new class of synthetic polymers which have a tree or star shape like structure, with a central core, interior branches and terminal groups which embellish the surface. It can be synthesized by a repetitive step-growth polymerization process. They are highly branched and monodisperse macromolecules. The structure of dendrimers mainly affected to its physical and chemical properties; so, it is widely used in biomedical, pharmaceuticals and industrial applications. In Drug delivery system, dendrimer plays major roles in ophthalmic, topical, transdermal, targeted drug delivery since last decade. Recent progress has been made in the application of biocompatible dendrimers to cancer and AIDS treatment, including their use as delivery systems for potent anticancer drugs such as cisplatin and doxorubicin, as well as agents for both boron neutrons capture therapy and photodynamic therapy. It is alsoinhibiting the entry of HIV and herpes simplex virus (HSV). This review articles giveswhole idea about various dendrimers, its type and its properties. Also it considers brief idea about various dendrimers used in various areas of research, treatment and diagnosis.
How to cite this article: A Shah, G Singhvi, Dendrimer: A Novel System in Pharmaceuticals, PharmaTutor, 2014, 2(1), 83-97
[ABSTRACT WITH CITATION] [VIEW AS HTML]
REFERENCES:
1.Buhleier EW, Wehner W, and Vogtle F. Cascade and Nonskid Chain-like Synthesis of Molecular Cavity Topologies 1978; Synthesis 55 (2): 155–158.
2.Khandare JJ et al. Dendrimer versus Linear Conjugate: Influence of Polymeric Architecture on the Delivery and Anticancer Effect of Paclitaxel. Bioconjug chem. 2006; 17 (6): 1464–1472.
3.Tomalia DA et al. A New Class of Polymers: Starburst-Dendritic Macromolecules. Polym J 1985; 17 (1): 117–132.
4.Peeyushkumar, Meena KP, PramodKumar, Champalal C, Devendra Singh T et al. Dendrimer: A Novel Polymer For Drug Delivery. Journal of Innovative trends in Pharmaceutical Sciences 2010; 1(6):252-269.
5.Zuhorn IS, Kalicharan R, Hoekstra D. Lipoplex-mediated transfection of mammalian cells occurs through the cholesterol- dependent clathrin-mediated pathway of endocytosis. J. Biol. Chem. 2002; 277: 18021–18028.
6.Passeno LM, Mackay ME, and Baker GL. Conformational Changes of Linear-Dendrimer Diblock Copolymers in Dilute Solution. Macromolecules 2006; 39 (2): 740–746.
7.Liu M and Fréchet JM. Designing Dendrimers for Drug Delivery. Pharm SciTechnolo Today 1999; 2 (10): 393–401.
8.Moure TH et al. Unique Behavior of Dendritic Macromolecules: Intrinsic Viscosity of Polyether Dendrimers. Macromolecules 1992; 25(9): 2401–2406.
9.Tack F.; Bakker A.; Maes S.; Dekeyser N. et al. Modified poly(propylene imine) dendrimers as effective transfection agents for catalytic DNA enzymes (DNAzymes).J. Drug Targeting 2006, 14(2), 69-86.
10.Mintzer, M.A.; Dane, E.L.; O'Toole, G.A.; Grinstaff, M.W. Exploiting dendrimer multivalency to combat emerging and re-emerging infectious diseases. Mol. Pharmaceutics 2012, 9(3), 342-54.
11.Jackie Fairley. Dendrimers for Drug Delivery: Animal and Human Health Applications [online]. 2012 (cited 2012 Aug 21). Available from: ausbiotech.org/userfiles/file/AgBio/Jackie%20Fairley%20presentation.pdf
12.Bourne N et al. Dendrimers, a New Class of Candidate Topical Microbicides with Activity against Herpes Simplex Virus Infection. Antimicrobial Agents and Chemotherapy. Antimicrob. Agents Chemother 2000; 4 (9): 2471–2474.
13.Patri AK, Majoros IJ, Baker JR. Dendritic polymer macromolecular carriers for drug delivery. CurrOpinChem Biol.2002; 6: 466-471.
14.Morgenroth F, Reuther E, Mullen K. Polyphenylene Dendrimers: From Three-Dimensional to Two-Dimensional Structures AngewandteChemie. International Edition in English 1997; 36 (6): 631-634.
15.Nanjwade BK, Hiren M. Dendrimers: Emerging polymers for drug-delivery systems. Eur J Pharm Sci. 2009; 38 (3): 185-196.
16.Naylor AM, Goddard WA, Kiefer GE, Tomalia DA. Starburst Dendrimers Molecular Shape Control. J. Am. Chem. Soc. 1989; 111: 2339-2341.
17.Newkome GR, Woosley BD, Moorefield CD et al. Supramolecular chemistry of flexible, dendritic-based structures employing molecular recognition. Chem. Commun. 1996; 2737-2738.
18.Sakthivel T, Toth I, Florence AT. Synthesis and physicochemical properties of lipophilic polyamide dendrimers, Pharm. Res. 1998; 15: 776-782.
19.Chen HT, Neerman MF, Simanek EE, Cytotoxicity, hemolysis and acute in vivo toxicity of dendrimers based on melamine, candidate vehicles for drug delivery. J. Am. Chem. Soc.2004; 126: 10044-10048.
20.Jevprasesphant R, Penny J, Jalal R, Attwood D etal.The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int. J. Pharm. 2003; 252: 263-266.
21.El-Sayed M, Ginski M, Rhodes C and Ghandehari H. Trans epithelial transport of poly (amidoamine) dendrimers across Caco-2 cell monolayers.S J. Control.Release, 2002; 81: 355–365.
22.Fischer Li Y, Ahlemeyer B, Krieglstein J, Kissel T. In vitro cytotoxicitytesting of polycations: influence of polymer structure on cell viability and shemolysis. Biomaterials, 2003; 24: 1121–1131.
23.Kobayashi HS, Kawamoto T, Saga N, Sato A et al. Positive effects of polyethylene glycol conjugation to generation-4 polyamidoamine dendrimers as macromolecular MR contrast agents. Magn. Reson. Med. 2001; 46: 781-788.
24.Petar R, Dvornic L, Douglas S, Michael J and Owen SP. Radially Layered Co poly (amid amine organ silicon) Dendrimers. United States Patent, 1998; 5: 739.
25.Choi Y, Thomas T, Kotlyar A and Baker JR. Synthesis and functional evaluation of DNA assembled polyamidoamine dendrimer clusters for cancer cell-specific targeting. Chem. Biol, 2005; 12: 35–43.
26.Brabander-van den Berg EMM, Meijer EW. Poly (propylene imine) Dendrimers. Large Scale Synthesis by Heterogeneously Catalyzed Hydrogenation. AngewChemInt Ed Engl, 1993; 32: 1308-1311.
27.Barbara K, Maria B. Dendrimers: properties and applications.ActaBiochim Pol, 2001; 48(1):199-208.
28.Ritzén A, Frejd T. Synthesis of a chiral dendrimer based on polyfunctional amino acids, Chem. Commun. 1999: 207-208.
29.Anne-Marie Caminade et al. ‘‘Janus’’ dendrimers: syntheses and properties. New J. Chem.2012; 36: 217–226.
30.Rajesh Babu V, Mallikarjun V, Nikhat SR, Srikanth G. Dendrimers: A New Carrier System for Drug Delivery. International Journal of Pharmaceutical and Applied Sciences, 2010; 1 (1):1.
31.Jain NK, Khopade AJ. Dendrimersas potential delivery systems for bioactives. In: N.K.Jain, Editor, Advances in controlled and novel drugdelivery. CBS Publishers & Distributors, 2001: 361–380.
32.Colinger M. Biological applications of dendrimers. Curr. Opin. Chem. Biol. 2002; 6: 742–748.
33.Umesh G, Hrushikesh A, Abhay A, Narendra J. A review of in vitro–in vivo investigations on dendrimers: the novel nanoscopic drug carriers Nanomedicine; Nanotechnology, Biology, and Medicine 2006; 2: 66– 73.
34.Tolia GT, Choi HH, Ahsan F. The role of dendrimers in drug delivery. Pharmaceut. Tech. 2008; 32: 88–98.
35.Vandamme TF and Brobeck L. Poly(amidoamine) Dendrimers as Ophthalmic Vehicles for Ocular Delivery of Pilocarpine Nitrate and Tropicamide. J. Control. Rel, 2005;102 (1): 23–38.
36.Bai S, Thomas C, Ahsan F. Dendrimers as a carrier for pulmonary delivery of enoxaparin, a low molecular weight heparin. J.Pharm. Sci.2007; 96: 2090–2106.
37.Emanuele D, Jevprasesphant AR, Penny RJ and Attwood D. J. Controlled Release, 2004; 95: 447-453.
38.Papagiannaros A, Dimas K, Papaioannou GT, Demetzos C. Doxorubicin-PAMAM dendrimer complex attached to liposomes: cytotoxic studies against human cancer cell lines. Int. J. Pharm. 2005; 302(1-2):29-38.
39.Harada A, Nishiyama N, Koyam H at al. Polyion complex micelles entrapping cationic dendrimer porphyrin: Effective photosensitizer for photodynamic therapy of cancer. J. Controlled Release, 2003; 93: 141–150.
40.Cheng Y et al. Transdermal Delivery of Nonsteroidal Anti-Inflammatory Drugs Mediated by Polyamidoamine (PAMAM) Dendrimers. J. Pharm. Sci. 2007; 96 (3): 595–602.
41.Chauhan AS et al. Dendrimer-Mediated Transdermal Delivery: Enhanced Bioavailability of Indomethacin. J. Control. Rel. 2003; 90 (3): 335–343.
42.Cheng Yiyun. Dendrimers as Potential Drug Carriers.Part I. Solubilization of Non-Steroidal Anti-Inflammatory Drugs in the Presence of Polyamidoamine Dendrimers, European Journal of Medicinal Chemistry, 2005; 40:1188–1192.
43.Gebhart CL, Kabanov AV. Evaluation of polyplexes as genetransfer agents. J Controlled Release, 2001; 73:401-416.
44.Morgan MT, Carnahan MA, Immoos CE, Ribeiro AA, Finkelstein S, Lee SJ, Grinstaff MW. Dendritic molecular capsules for hydrophobic compounds. J. Am. Chem. Soc. 2003; 125: 15485–15489.
45.Morgan MT, Carnahan MA, Finkelstein S, Prata CA, Degoricija L, Lee SJ, Grinstaff MW. Dendritic supramolecular assemblies for drug delivery. Chem. Commun. (Camb.), 2005; 4309–4311.
46.Morgan MT, Nakanishi Y, Kroll DJJ, Griset AP, Carnahan MA, WathierM at. al. Dendrimer-encapsulated camptothecins: increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity in vitro. Cancer Res. 2006; 66: 11913–11921.
47.Wang F, Bronich TK, A V Kabanov, R D Rauh, J Roovers. Synthesis and evaluation of a star amphiphilic block copolymer from poly (epsiloncaprolactone) and poly(ethylene glycol) as a potential drug delivery carrier. Bioconjug. Chem. 2005; 16: 397–405.
48.Ooya T, Lee J, Park K. Hydrotropic dendrimers of generations 4 and 5: synthesis, characterization, and hydrotropic solubilization of paclitaxel. Bioconjug. Chem.2004; 15: 1221–1229.
49.Neerman MF, Chen HT, Parrish AR, Simanek EE. Reduction of drug toxicity using dendrimers based on melamine. Mol. Pharm. 2004; 1: 390–393.
50.Gurdag S, Khandare J, Stapels S, Matherly LH, Kannan RM. Activity of dendrimer-methotrexate conjugates on methotrexate-sensitive and -resistant cell lines. Bioconjug. Chem. 2006; 17: 275–283.
51.Khandare JJ, Jayant S, Singh A, Chandna P, Wang Y, Vorsa N, Minko T. Dendrimer versus linear conjugate: influence of polymeric architecture on the delivery and anticancer effect of paclitaxel. Bioconjug. Chem. 2006; 17: 1464–1472.
52.Papagiannaros A, Dimas K, Papaioannou GT, Demetzos C. Doxorubicin- PAMAM dendrimer complex attached to liposomes: cytotoxic studies against human cancer cell lines. Int. J. Pharm. 2005; 302: 29–38.
53.Sonke S, Tomalia DA. Dendrimers in biomedical applications reflections on the Field,Advanced Drug Delivery Reviews , 2005; 57: 2106–2129.
54.Barth RF, Adams DM, Soloway AH, Alam F, Darby MV. Boronated starburst dendrimer monoclonal antibody immunoconjugates.Bioconjugate Chem. 1995; 5: 58–66.
55.Witvrouw M, Fikkert V, Pluymers W, et al. Polyanionic (iepolysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle. MolPharmacol, 2000; 58 (5): 1100-1108.
56.Bourne N, Stanberry LR, Kern ER, et al. Dendrimers, a new class of candidate topical microbicides with activity against herpes simplex virus infection. Antimicrob Agents Chemother, 2000; 40 (9): 2471-2474.
57.Duncan R., Izzo L. Dendrimer biocompatibility and toxicity. Adv. Drug Deliv. Rev.2005; 57: 2215–2237.
58.Albrecht M, Gossage RA, Lutz M, Spek Al, Van Koten G. Diagnostic organometallic and metallodendritic materials for SO2 gas detection: reversible binding of sulfur dioxide toarylplatinum(II) complexes. ChemEur J. 2000; 6: 1431-1445.
59.Tanaka K, Kitamura N, Chujo Y. Bimodal quantitative monitoring for enzymatic activity with simultaneous signal increases in 19F NMR and fluorescence using silica nanoparticle-based molecular probes.Bioconjug Chem. 2011, Aug 17; 22(8):1484-90.
60.Schumann H, Wassermann BC, Schutte S, Velder J, Aksu Y, Krause W. Synthesis and characterization of water-soluble tin-based metallodendrimers. Organometallics, 2003; 22: 2034-41.
61.Krause W, Hackmann-Schlichter N, Maier FK, Muller R. Dendrimers in diagnostics. Topics Curr Chem. 2000; 210: 261–308.
62.Weir MG, Myers VS, Frenkel AI, Crooks RM. In situ X-ray absorption analysis of 1.8 nm dendrimer-encapsulated Pt nanoparticles during electrochemical CO oxidation. Chemphyschem. 2010;11(13):2942-2950.
63.Wiener EC, Brechbiel MW, Brothers H, Magin RL, Gansow OA, Tomalia DA. Dendrimer-based metal chelates: a new class ofmagnetic resonance imaging contrast agents. MagnReson Med, 1994; 31: 1-8.
64.Wiener EC, Konda S, Shadron A, Brechbiel M, Gansow O. Targeting dendrimer– chelates to tumors and tumor cells expressing the highaffinityfolate receptor. Invest Radiol, 1997; 32: 748-54.
65.Venditto VJ, Regino CA, Brechbiel MW. PAMAM dendrimer based macromolecules as improved contrast agents. Mol Pharm . 2005; 2: 302 - 311.
66.Erika B, Luis A. Godínez. Modified Surfaces with Nano-Structured Composites of Prussian blue and Dendrimers; New Materials for Advanced Electrochemical Applications. Int. J. Electrochem. Sci. 2011; 6:1–36.
67.Omotayo A, Priscilla G Baker, Bhekie B et al. The Application of Electrodeposited Poly (Propylene imine) Dendrimer as an Immobilisation Layer in a Simple Electrochemical DNA Biosensor. Int. J. Electrochem. Sci. 2011; 6: 673-683.
68.Jain NK, Gupta U. Application of dendrimer-drug complexation in the enhancement of drug solubility and bioavailability. Expert Opin Drug MetabToxicol, 2008; 8: 1035-1045.
69.ChengYiyunab, XuTongwen. Dendrimers as Potential Drug Carriers. Part I. Solubilization of Non-Steroidal Anti-Inflammatory Drugs in the Presence of Polyamidoamine Dendrimers. European Journal of Medicinal Chemistry, 2005; 40: 1188–1192.
70.McCarthy TD, Karellas P, Henderson SA, Giannis M et al. Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol Pharm. 2005; 2: 312-8.
71.Singh P. Dendrimers and their applications in immunoassays and clinical diagnostics. Biotech Appl Biochem. 2007; 48: 1-9.
72.Super Tang MX, Redemann CT, Szoka, Jr FC. In vitro gene deliveryby degraded polyamidoamine dendrimers. Bioconjug Chem. 1996; 7:703.
73.Verweij, j. Docetaxel (Taxotere): a new anti-cancer drug with promising potential. British Journal of Cancer, 1994, 70(2), 183-4.
.png)
